Table 1. Sample size calculations.
N required to show with sufficient power (0.8) an improvement in a DE50-MD biomarker towards WT levels with any given treatment. Sample sizes were calculated for the principal component analysis output (performed on blood-borne CK activity, MYOM3 quantity, MSTN concentration, and miR-1, -133a and -206 relative quantity) and for each individual biomarker that was significantly elevated in DE50-MD compared to WT blood samples for dogs aged 3–18 months. (CK: creatine kinase; MSTN: myostatin; MYOM3: myomesin-3; WT: wild type.)
| Percentage
improvement towards WT concentrations |
||||
|---|---|---|---|---|
| (N per genotype) | ||||
| Biomarker | 25% | 50% | 75% | 100% |
| Principal component | 3 | 2 | 2 | 2 |
| CK activity (Log10 U/l) | 3 | 2 | 2 | 2 |
| MYOM3 (AU) | 6 | 3 | 3 | 2 |
| MSTN (ng/ml) | 7 | 3 | 3 | 2 |
| miR-1 (Log10 relative quantity) | 5 | 3 | 2 | 2 |
| miR-133a (Log10 relative quantity) | 7 | 3 | 3 | 2 |
| miR-206 (Log10 relative quantity) | 4 | 2 | 2 | 2 |